CD274 and gastric cancer: For instance, CHECKMATE-649 demonstrated a significant OS benefit of adding nivolumab to chemotherapy in patients with unresectable GEJ and gastric cancer in PD-L1 combined positive score (CPS) ≥ 1 nested subgroup, the PD-L1 CPS ≥ 5 nested subgroup, and all comers, leading to the approval of the regimen for all patients regardless of the PD-L1 level.26